NCT07138677Completed
Safty and Efficacy of MCI Network Guided TMS for Early Alzheimer's Disease: A Randomized, Double-blind Trial
The Safty and Efficacy of Mild Cognitiive Impairment Network Guided Transcranial Magnetic Stimulations for Patients With Early Alzheimer's Disease (SENS-eAD): A Randomized, Double-blind Trial
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
Estimate the safty and efficacy of personalized network neuronavigated transcranial magnetic stimulations in early Alzheimer's disease patients
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 30 Apr 2025
- Start date
- 20 Jul 2025
- Primary completion date
- 14 Mar 2026
- Lead sponsor
- Anhui Medical University
- Diseases
- Alzheimer disease
- NCT number
- NCT07138677
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 20 Jul 2025 to the primary completion date, 14 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, or any implanted medical device that is incompatible with MRI.
Other illness
- Depression or other psychiatric disorders.
- History of head injury, stroke, epilepsy or other neurologic disease.
- History of unexplained loss of consciousness.
- Family history of medication refractory epilepsy.
- History of substance abuse within the last 6 months.
Other
- Recevied rTMS treatment in the past 3 months.
- Organic brain defects on T1 or T2 images.
Who the study is looking for
- Subject diagnosed as either mild cognitive impairment due to AD or mild AD dementia based on National Institute on Aging-Alzheimer's Association criteria.
- MMSE score 18-28.
- CDR score 0.5-1.
- On stable treatment with IAChE or memantine for at least 6 months.
- Literate in Han Chinese.
Age in the registry: 45 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Anhui Medical University Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.